Dr. Jonasch on Next Steps With MK-6482 in Von Hippel-Lindau Disease–Associated RCC

Eric Jonasch, MD, discusses the next steps with the potent, selective, small molecule HIF-2α inhibitor MK-6482 in Von Hippel-Lindau disease–associated renal cell carcinoma.

Website: https://www.onclive.com
Twitter: https://twitter.com/OncLive
Facebook: https://www.facebook.com/OncLive/
LinkedIn: https://www.linkedin.com/company/onclive

• 类别